You are here: Industry Insights > Vaccitech

News List

Biotech start-up Vaccitech files for US IPO expresspharma
April 12, 2021
Vaccitech owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca.
Vaccitech Doses First Patient in HBV002 for Chronic HBV americanpharmaceuticalreview
February 04, 2021
Vaccitech announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with CHB infection.
Vaccitech Receives UK Grant to Support COVID-19 Tech Platform contractpharma
August 28, 2020
Vaccitech's new platform induces leading antibody and cell-mediated immune responses, two arms of the immune system known to protect against disease.
Vaccitech begins Phase 1 clinical study of VTP-300 immunotherapeutic to treat chronic Hepatitis B expresspharma
June 24, 2020
Once the VTP-300 prime dose is confirmed, Vaccitech plans to initiate a Phase 1b/2a study, HBV002, in Q3 2020.
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy b3cnewswire
March 23, 2020
Vaccitech Limited and the University of Oxford today announce initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in patients with metastatic castration resistant prostate cancer (mCRPC).
Vaccitech Oncology Limited Enters Collaboration with Cancer Research UK to Fund a Phase I/IIa Clinical Trial as First-Line NSCLC Therapy b3cnewswire
December 25, 2019
Vaccitech Ltd announced today that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT) ...
CRUK partners with Vaccitech on NSCLC immunotherapeutic vaccine pharmaceutical-technology
December 19, 2019
Vaccitech has signed a partnership with Cancer Research UK (CRUK) to clinically advance VTP-600, the former’s immunotherapy vaccine candidate, for patients with non-small cell lung cancer (NSCLC).
Vaccitech Provides Update on Clinical Progress for its Two Phase 2 Universal Influenza Studies b3cnewswire
November 26, 2019
Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases, reports successful recruitment and vaccination for ...
Vaccitech Appoints CEO contractpharma
August 28, 2019
Bill Enright, former CEO at Gaithersburg-based Altimmune, brings experience in progressing science research, and development through executive and management roles.
Vaccitech Universal Flu Vaccine Passes Phase 2b Clinical Development Milestones americanpharmaceuticalreview
June 06, 2019
Vaccitech has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100) to the first participants in a Flu 010 study – a Phase 2b, randomized, double-blind, placebo controlled, influenza challenge study being conducted in Antwerp, Belgiu

Previous page 1 2 Next page